Clinical Trials Logo

Hyperkinesis clinical trials

View clinical trials related to Hyperkinesis.

Filter by:

NCT ID: NCT01721330 Terminated - Clinical trials for Attention Deficit Hyperactivity Disorder

A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder

Start date: November 2012
Phase: Phase 4
Study type: Interventional

The primary aim of this study is to assess whether naltrexone as a monotherapy is effective in treating ADHD in adults. Medications that increase dopamine are often effective treatments for ADHD. Since naltrexone is a kappa opioid receptor antagonist, it increases dopamine in the brain. The investigators predict that naltrexone as a monotherapy will be effective for ADHD symptoms in adults with ADHD. The investigators also plan to assess the effects of naltrexone on dopamine as measured by changes in serum prolactin. The investigators predict that naltrexone will increase dopamine as indexed by decreases in serum prolactin. This study will be a six-week, double-blind, placebo-controlled pilot study with adults 18-55 years of age with ADHD.

NCT ID: NCT01156051 Terminated - Insomnia Clinical Trials

Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

Start date: June 2010
Phase: Phase 4
Study type: Interventional

This study seeks to determine, using special sleep tests (polysomnography and actigraphy) if guanfacine extended release is able to improve nighttime sleep in children with ADHD - associated insomnia while improving daytime ADHD symptoms. Male and female children with diagnosed or suspected ADHD with sleep problems (difficulty falling asleep, difficulty staying asleep, or less than expected hours of sleep) will be recruited. After obtaining informed consent and assent (when appropriate) and after discontinuation of excluded medications, children will have evaluations of his or her sleep and evaluations confirming the ADHD diagnosis. Children who successfully pass screening will be enrolled into the double-blind, placebo-controlled, randomized investigation with 50% of participants receiving guanfacine extended release and 50% of participants receiving matching placebo. Using a flexible-dose optimization design based on ADHD symptom improvement and medication tolerability, the dose will be adjusted between 1 to 4 mg over the course of four weeks. At the end of medication adjustment (week 4 or 5), ADHD questionnaires, sleep questionnaires, and sleep tests will be repeated and analyzed. The medication will be weaned over the course of the following 3-10 days.

NCT ID: NCT01127646 Terminated - Clinical trials for Attention Deficit Hyperactivity Disorder

A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents

EMD
Start date: June 2010
Phase: Phase 4
Study type: Interventional

The main purpose of the study is to help to understand the effect on children and adolescents who are stable on treatment with atomoxetine or osmotic-release oral system (OROS) methylphenidate for attention-deficit/hyperactivity disorder (ADHD) of not taking the medication for a maximum of 6 days over a 28-day study treatment period.

NCT ID: NCT01017263 Terminated - Obesity Clinical Trials

Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity

Start date: December 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study to assess the effects of chronic administration of Vyvanse (lis-dexamphetamine) on glucose metabolism in a sample of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) who also have glucose intolerance and are obese.

NCT ID: NCT00965419 Terminated - Clinical trials for Attention Deficit Hyperactivity Disorder

A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder

Start date: September 2009
Phase: Phase 2/Phase 3
Study type: Interventional

The primary purpose of the study is to assess long-term safety and tolerability of Edivoxetine in pediatric participants with attention deficit hyperactive disorder (ADHD).

NCT ID: NCT00907218 Terminated - Smoking Cessation Clinical Trials

Chantix in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD)

Start date: April 2009
Phase: Phase 4
Study type: Interventional

The purpose of this research study is to learn about the efficacy of a medication called varenicline (Chantix) in treating ADHD in adults and in reducing cigarette smoking in adults with ADHD. The investigators hypothesize that ADHD symptomatology in adults with ADHD will be improved with varenicline treatment. The investigators also hypothesize that varenicline treatment will result in significant reductions in cigarette smoking. Another objective of this study is to more fully evaluate the response and tolerability to varenicline in this group of cigarette smoking adults with ADHD.

NCT ID: NCT00885040 Terminated - Healthy Volunteer Clinical Trials

Investigation of Neurofeedback With Real-Time fMRI in Healthy Volunteers and Patients With Hyperkinetic Movement Disorders

Start date: April 17, 2009
Phase:
Study type: Observational

Background: - Many people can learn to use feedback about brain activity to modify that activity, but is it not known if people with Tourette syndrome can modify their brain activity. - Researchers have evidence that certain areas of the brain are involved in causing tics in people with Tourette syndrome. If people with Tourette syndrome can use feedback about brain activity to modify activity in those parts of the brain, they may be able to modify their brain activity to help control the tics. Objectives: - To determine if people with and without Tourette syndrome can learn to use thought to control brain activity. - To test whether people who have Tourette syndrome can learn to control brain activities, possibly helping to control tics. Eligibility: - Healthy volunteers ages 18 and older who are right-handed and are willing to not consume caffeine or alcohol for 24 hours before the study visit. - Patients with Tourette syndrome who have tics that can be observed and studied. - All participants must be able to undergo magnetic resonance imaging (MRI) scans. Design: - Healthy volunteers (two visits to the NIH Clinical Center over a 2- to 4-week period; visit may last up to 3 hours): - Screening visit, including physical examination and medical history, and a magnetic resonance imaging (MRI) scan if the individual has not had one performed at the National Institutes of Health in the past year. - Study visit: Functional MRI (fMRI) scan to allow researchers to see if volunteers can learn to control their brain activity during a scan. Volunteers will be asked to complete tasks as directed during the fMRI scan. - Patients with Tourette syndrome (three or four outpatient visits over a 4- to 6-week period; each visit may last up to 4 hours): - Screening visit, including physical examination and medical history, and an MRI scan if the individual has not had one performed at the National Institutes of Health in the past year. - Evaluation visit to ask questions about Tourette symptoms and to have patients complete questionnaires about their tics and their mental health. - Study visit: fMRI scan to allow researchers to see if patients can learn to control their brain activity during a scan. Patients will be asked to complete tasks as directed during the fMRI scan. - Final visit: Researchers will ask questions about tic symptoms, have patients complete questionnaires, and perform a brief exam. Afterward, patients will have an fMRI scan similar to the previous one. - All participants will be paid a small amount of money in compensation for their participation in the study.

NCT ID: NCT00687609 Terminated - Clinical trials for Attention Deficit Hyperactivity Disorder

Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE

PEACE
Start date: September 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in adolescents with ADHD and comorbid cannabis abuse.

NCT ID: NCT00684931 Terminated - Clinical trials for Attention Deficit Disorder With Hyperactivity

Cerebellar Loops and Attention Deficit Hyperactivity Disorder (ADHD)

TDA/H
Start date: February 2008
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the integrity of connectivity between the neocortex and the cerebellum in the Attention Deficit Hyperactivity Disorder (ADHD). Fibers integrity will be measured using magnetic Resonance Imaging Techniques.

NCT ID: NCT00554385 Terminated - Clinical trials for Attention-Deficit/Hyperactivity Disorder

A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Start date: November 2007
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the long-term safety and tolerability of ABT-089 in children with ADHD.